The economic slowdown in the past couple of months could lead to long-term changes for Boston's innovation industry, giving some tech startups the chance to stay independent and pursue an IPO, while pushing biotech firms toward M&A, according to experts. The time is also ripe for drug companies that have cash on hand and want to add new product lines to their portfolio to snap up for discounted prices, says Goodwin’s Life Sciences Partner Robert Puopolo. Read the Boston Business Journal article here.